KPT 9274

Drug Profile

KPT 9274

Alternative Names: KPT-9274; PAK4/NAMPT dual inhibitors

Latest Information Update: 17 Jun 2016

Price : $50

At a glance

  • Originator Karyopharm Therapeutics
  • Class Antineoplastics; Small molecules
  • Mechanism of Action Nicotinamide phosphoribosyltransferase inhibitors; P21 activated kinase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Non-Hodgkin's lymphoma; Solid tumours

Most Recent Events

  • 01 May 2016 Phase-I clinical trials in Non-Hodgkin's lymphoma (Late-stage disease) in USA (PO) (NCT02702492)
  • 01 May 2016 Phase-I clinical trials in Solid tumours (Late-stage disease) in USA (PO) (NCT02702492)
  • 16 Apr 2016 Pharmacodynamics data from a preclinical study presented at the 107th Annual Meeting of the American Association for Cancer Research (AACR-2016) (3182695; 3182754)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top